Skip to main content Skip to footer

Orexo press releases

Interim Report January-March 2016

21 April 2016 at 08:00 – Regulatory – Report – Q1

Interim Report January-March 2016

Report from Orexo AB’s Annual General Meeting, 15 April 2016

15 April 2016 at 19:30 – Regulatory – General Meeting

Report from Orexo AB’s Annual General Meeting, 15 April 2016

Orexo’s Annual Report for 2015 released

22 March 2016 at 11:45 – Regulatory – Report

Orexo’s Annual Report for 2015 released

AstraZeneca acquires all rights to Orexo´s OX-CLI project

17 March 2016 at 08:00 – Regulatory

AstraZeneca acquires all rights to Orexo´s OX-CLI project

Notice of Annual General Meeting of Orexo

11 March 2016 at 10:00 – Regulatory – General Meeting

Notice of Annual General Meeting of Orexo

Number of shares and votes in Orexo

29 February 2016 at 17:35 – Regulatory

Number of shares and votes in Orexo

Full year report January-December 2015

28 January 2016 at 08:40 – Regulatory – Report – Q4

Full year report January-December 2015

New Abstral® partner in the US

20 November 2015 at 15:15

New Abstral® partner in the US

Orexo Settles Abstral® US Patent Litigation with Actavis

27 October 2015 at 08:30 – Regulatory

Orexo Settles Abstral® US Patent Litigation with Actavis

Interim report January-September 2015

22 October 2015 at 08:00 – Regulatory – Report – Q3

Interim report January-September 2015

Number of shares and votes in Orexo

31 July 2015 at 08:00 – Regulatory

Number of shares and votes in Orexo

Interim report January-June 2015

10 July 2015 at 08:00 – Regulatory – Report – Q2

Interim report January-June 2015

Number of shares and votes in Orexo

30 June 2015 at 18:15 – Regulatory

Number of shares and votes in Orexo

President and CEO

Nikolaj Sørensen

EVP & Chief Financial Officer

Fredrik Järrsten